Sunbird Bio is happy to announce the appointment of Peter J. Maimonis, Ph.D. as its new Chief Technology Officer, effective 24th October 2022. Peter brings over 3 decades of experience developing biomarker assays from concept to regulatory approval. Peter will be responsible for guiding Sunbird Bio's development efforts as they move towards bringing their novel neurodegenerative disease diagnostic assays to market.

Prior to joining Sunbird Bio, Peter has held senior positions at Chiron Diagnositcs, Bayer Health Care, Decision Biomarkers, and most recently Metamark Genetics, where he led scientific and research efforts for their oncology program.